<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04982419</url>
  </required_header>
  <id_info>
    <org_study_id>NEPH-019-20S</org_study_id>
    <secondary_id>1I01CX002045-01</secondary_id>
    <nct_id>NCT04982419</nct_id>
  </id_info>
  <brief_title>Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial</brief_title>
  <acronym>RICH</acronym>
  <official_title>Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, double-blind, sham-controlled, multicenter, randomized clinical trial&#xD;
      is to study the effects of remote ischemic preconditioning on contrast-associated acute&#xD;
      kidney injury, functional capacity, and major adverse kidney events in in patients with&#xD;
      congestive heart failure undergoing cardiac catheterization and/or percutaneous coronary&#xD;
      intervention.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The RICH Trial is a prospective, multicenter, randomized clinical trial to determine the&#xD;
      effect of remote ischemic preconditioning on contrast associated acute kidney injury, and to&#xD;
      characterize the effect of remote ischemic preconditioning on brain natriuretic peptide,&#xD;
      functional capacity at one month, and major adverse kidney events (persistent renal&#xD;
      dysfunction, renal replacement therapy, and death) at three months in patients with&#xD;
      congestive heart failure with reduced left ventricular ejection fraction undergoing coronary&#xD;
      angiography and/or percutaneous coronary intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2027</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2026</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Eligible patients will be randomized to RIPC or sham-RIPC.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Contrast-associated acute kidney injury</measure>
    <time_frame>24 and 48 hours time points</time_frame>
    <description>The investigators define contrast-associated acute kidney injury as a relative increase in serum creatinine of 0.3mg/dl compared with initial creatinine at 48 hours time point after coronary angiography and/or PCI. The will obtain levels of serum creatinine at baseline, then at 24 and 48 hours time points.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>6 minute walk distance</measure>
    <time_frame>1 month</time_frame>
    <description>At one month follow-up, 6 minute walk test will be used to determine total distance walked in 6 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse kidney events</measure>
    <time_frame>3 months</time_frame>
    <description>Persistent renal dysfunction, renal replacement therapy, and death will be assessed at 3 months (90 days) to determine major adverse kidney events (MAKE90).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain Natriuretic Peptide (BNP)</measure>
    <time_frame>24 and 48 hours time points</time_frame>
    <description>BNP is a hormone that is primarily secreted from the ventricular myocardium in response to hemodynamic stimuli such as ventricular volume expansion and pressure overload. The investigators will obtain levels of serum BNP at baseline, then at 24 and 48 hours.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Acute Kidney Injury</condition>
  <condition>Heart Failure</condition>
  <condition>Contrast Induced Nephropathy</condition>
  <condition>Coronary Angiography</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>Remote ischemic preconditioning</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 cycles of blood pressure cuff inflations to occlusive pressure of 200 mmHg for 5 minutes and deflation for 5 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham remote ischemic preconditioning</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>3 cycles of blood pressure cuff inflations to non-occlusive pressure of 60 mmHg for 5 minutes and deflation for 5 minutes (Control)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Remote ischemic preconditioning</intervention_name>
    <description>3 cycles of blood pressure cuff inflations to occlusive pressure of 200 mmHg for 5 minutes and deflation for 5 minutes</description>
    <arm_group_label>Remote ischemic preconditioning</arm_group_label>
    <other_name>RIPC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham remote ischemic conditioning</intervention_name>
    <description>3 cycles of blood pressure cuff inflations to non-occlusive pressure of 60 mmHg for 5 minutes and deflation for 5 minutes (Control)</description>
    <arm_group_label>Sham remote ischemic preconditioning</arm_group_label>
    <other_name>Sham-RIPC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years&#xD;
&#xD;
          -  Diagnosis of heart failure with reduced LVEF &lt;50%&#xD;
&#xD;
          -  Pre-procedure intravenous normal saline fluid restriction status&#xD;
&#xD;
          -  Society for Cardiovascular Angiography and Interventions (SCAI) AKI risk score (&gt;1%)&#xD;
&#xD;
          -  Referral for coronary angiogram and/or PCI&#xD;
&#xD;
          -  Suspected stable coronary artery disease or acute coronary syndrome&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to give informed consent&#xD;
&#xD;
          -  Unstable BP (SBP &gt; 200 or &lt;80 mmHg) at the time of enrolment&#xD;
&#xD;
          -  Upper limb peripheral arterial disease&#xD;
&#xD;
          -  Unavailability of at least one arm for RIPC/Sham-RIPC application&#xD;
&#xD;
          -  Kidney transplant&#xD;
&#xD;
          -  Renal disease requiring dialysis&#xD;
&#xD;
          -  Prior exposure to contrast media within 72hrs preceding coronary angiography&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Prisoner&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oladipupo Olafiranye, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oladipupo Olafiranye, MD</last_name>
    <phone>(412) 688-6000</phone>
    <email>Oladipupo.Olafiranye@va.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Oussama Khalifa, MD</last_name>
    <phone>(412) 360-6191</phone>
    <email>oussama.khalifa@va.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oladipupo Olafiranye, MD</last_name>
      <phone>412-688-6000</phone>
      <email>Oladipupo.Olafiranye@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Oussama Khalifa, MD</last_name>
      <phone>(412) 360-6191</phone>
      <email>oussama.khalifa@va.gov</email>
    </contact_backup>
    <investigator>
      <last_name>Oladipupo Olafiranye, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hunter Holmes McGuire VA Medical Center, Richmond, VA</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ion Jovin</last_name>
      <phone>804-675-5419</phone>
      <email>ion.jovin@va.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 26, 2021</study_first_submitted>
  <study_first_submitted_qc>July 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Contrast-induced acute kidney injury</keyword>
  <keyword>Congestive heart failure</keyword>
  <keyword>Contrast induced nephropathy</keyword>
  <keyword>Coronary angiography</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <keyword>Coronary artery disease</keyword>
  <keyword>Remote ischemic conditioning</keyword>
  <keyword>acute coronary syndrome</keyword>
  <keyword>Acute kidney injury</keyword>
  <keyword>Major adverse kidney events</keyword>
  <keyword>Ischemic preconditioning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

